CIRCNOVA, INC SECURES INVESTMENT FROM MICHIGAN RISE

East Lansing, MI – CircNova, a Detroit-based biotechnology company, has secured an investment from Michigan Rise Pre-Seed Fund III as part of the Company’s pre-seed financing round.

CircNova uses their proprietary artificial intelligence (AI) engine to predict and design the structure of circular, non-coding RNA (ncRNA) sequences for the purpose of generating novel RNA therapeutics which have the potential to treat diseases caused by traditionally undruggable targets. The company is led by co-founders Crystal Brown (CEO), Steven Schwartz (CTO) and Joseph DeAngelo (CSO).

“CircNova's AI NovaEngine™ platform has the potential to enable entirely new therapeutic paradigms utilizing circular, ncRNA by addressing major challenges which currently exist in the field around predicting the structure and function of non-coding RNA sequences. Their platform can provide major competitive advantages to biotech companies in terms of the speed and precision of their drug discovery processes,” said Matt Okoneski, Senior Venture Associate at Michigan Rise. “CircNova’s focus on advancing the field of circular, ncRNA-based therapeutics puts the company on the forefront of programmable medicine.”

The investment from Michigan Rise will support CircNova’s R&D operations as well as facilitate future staffing initiatives.

About Michigan Rise 

Michigan Rise is a wholly owned venture capital subsidiary of the Michigan State University (MSU) Research Foundation, operated in partnership with the Michigan Economic Development Corporation (MEDC). Michigan Rise provides early-stage funding to innovative companies that have the potential to transform industries and create jobs in Michigan. 

About CircNova, Inc.

CircNova, Inc. is a deep biotechnology start-up combining AI, cutting edge scientific innovation, and modern drug development techniques to develop circular, non-coding RNA therapeutics to address unmet clinical needs.